Immunology and immunotherapy approaches for prostate cancer

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.

Original languageEnglish
Pages (from-to)224-236
Number of pages13
JournalProstate Cancer and Prostatic Diseases
Volume10
Issue number3
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Allergy and Immunology
Immunotherapy
Prostatic Neoplasms
T-Lymphocytes
Androgens
Neoplasms
Active Immunity
Neoplasm Antigens
Antigen-Presenting Cells
Prostate-Specific Antigen
Therapeutics
Clinical Trials
Antigens

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Immunology and immunotherapy approaches for prostate cancer. / Elkord, Eyad.

In: Prostate Cancer and Prostatic Diseases, Vol. 10, No. 3, 09.2007, p. 224-236.

Research output: Contribution to journalReview article

@article{0b94209a4c3f48deb89c2f48375acb48,
title = "Immunology and immunotherapy approaches for prostate cancer",
abstract = "Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate na{\"i}ve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33{\%} of incident cancer cases and about 9{\%} of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.",
author = "Eyad Elkord",
year = "2007",
month = "9",
doi = "10.1038/sj.pcan.4500964",
language = "English",
volume = "10",
pages = "224--236",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Immunology and immunotherapy approaches for prostate cancer

AU - Elkord, Eyad

PY - 2007/9

Y1 - 2007/9

N2 - Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.

AB - Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.

UR - http://www.scopus.com/inward/record.url?scp=34548421985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548421985&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500964

DO - 10.1038/sj.pcan.4500964

M3 - Review article

VL - 10

SP - 224

EP - 236

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 3

ER -